BridgeBio Pharma (NASDAQ:BBIO) shares rose after it announced positive results from its late-stage study of BBP-418 on patients with limb-girdle muscular dystrophy type 2I/R9. The study successfully ...
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates ...
Novartis AG will acquire Avidity Biosciences, Inc. for $12bn, aiming to strengthen its neuroscience franchise and xRNA strategy with late-stage muscle disease assets. The deal brings three late-stage ...
(Reuters) -BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage ...
Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
R1 calpain3-related is extremely rare, and its prenatal management is unclear. A primigravida in her late 30s with LGMD R1 calpain3-related was referred to our hospital during the first trimester.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results